News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received an average "Buy" rating from brokerages, with an average 12-month price target of $11.50. Institutional investors hold a significant portion of the stock, and several firms increased their positions recently. The company also surpassed its latest quarterly earnings …
This page provides a comprehensive overview of Aclaris Therapeutics, Inc. (ACRS) stock, including its current price, historical data, key statistics, and company profile. Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, with several drug candidates in various trial …
Aclaris Therapeutics reported a widened net loss of $41.329 million for the first half of 2026, primarily due to increased research and development (R&D) spending on its immuno-inflammatory programs like bosakitug, ATI-052, modzatinib, and ATI-9494. Despite the losses, the company maintains $170.6 million in …
Aclaris Therapeutics Inc (NASDAQ: ACRS) reported a second-quarter EPS of $-0.150, surpassing analyst estimates by $0.01. The company also exceeded revenue expectations, bringing in $1.6M against a consensus of $1.38M. Aclaris Therapeutics' stock has shown strong performance, increasing by 29.010% in the last three …
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has been granted Fast Track Designation by the FDA for its investigational drug modzatinib, intended for the treatment of moderate to severe lichen planus. This designation will expedite the development and review process for the therapy, which currently has …
Aclaris Therapeutics Inc. (NASDAQ:ACRS) has received Fast Track Designation from the FDA for its drug modzatinib (ATI-2138) to treat moderate to severe lichen planus. This designation will accelerate the development and review process for the drug, which addresses an unmet medical need as there …
This press release from Aclaris Therapeutics announces its financial results for the second quarter of 2026, alongside corporate and clinical updates. The report will likely detail key financial metrics, provide insights into their ongoing clinical trials, and offer a broader corporate overview for investors …
Aclaris Therapeutics reported a Q2 2026 net loss of $21.5 million, with cash, cash equivalents, and marketable securities totaling $170.6 million as of June 30, 2026. The company expects its cash runway, bolstered by an additional $40.2 million from ATM sales, to fund operations …
Aclaris Therapeutics, Inc. (ACRS) announced its Q2 revenue of $1.6 million, surpassing the FactSet estimate of $1.4 million. The biopharmaceutical company also recently received Fast-Track Designation for its inflammation treatment, Modzatinib, and was added to several Russell and S&P indices. The company is engaged …
Aclaris Therapeutics' Chief Scientific Officer, Roland Kolbeck, had 36,375 restricted stock units vest, converting into common shares on August 1, 2026. Of these, 12,385 shares were withheld for tax obligations at $5.20 per share. Kolbeck still holds 109,125 RSUs that will vest in future …
This article provides an overview of market sentiment for Aclaris Therapeutics (ACRS), highlighting key signals such as analyst consensus, short interest, options flow, and insider activity. Analysts show an "Outperform" consensus with an average price target significantly above the current price, while short interest …
Aclaris Therapeutics Inc (ACRS) has a weak financial status and low operating efficiency, ranking 281 out of 385 in the Biotechnology & Medical Research industry with a current financial score of 6.19. Despite this, its latest quarterly revenue increased by 37.18% year-over-year to $2.00M, …
This article provides historical dividend and stock split information for Aclaris Therapeutics Inc (ACRS). It notes that Aclaris Therapeutics has not distributed any dividends over the past five years and contains no data regarding past dividend payments or stock splits.
This article provides a detailed cash flow statement for Aclaris Therapeutics Inc (ACRS), including operating, investing, and financing cash flows, presented both quarterly and annually. It also defines these cash flow components and highlights Aclaris Therapeutics Inc's performance in each area, such as its …
This article provides a revenue breakdown for Aclaris Therapeutics Inc (ACRS), detailing its business segments. As of the latest disclosed information, the company generated $5.95 million (76.08%) from Licensing and $1.87 million (23.92%) from Laboratory Research Revenue. Regional revenue data has not yet been …
This article analyzes the institutional confidence in Aclaris Therapeutics Inc (ACRS), noting its score of 7.00, which ranks 80th in its industry. Institutional shareholding decreased by 32.53% quarter-over-quarter, with James Simons being the largest institutional shareholder. The article lists key institutional shareholders and their …
Piper Sandler has reiterated its Buy rating on Aclaris Therapeutics (ACRS.US) while maintaining a target price of $11. This indicates continued confidence in the company's prospects from the investment firm.
Piper Sandler analyst Biren Amin has reiterated a Buy rating on Aclaris Therapeutics (ACRS) with an $11.00 price target. This comes despite negative insider sentiment, indicated by recent share sales, and the company reporting a GAAP net loss of $19.82 million in its latest …
Search by ticker symbol or company name and select a result to open its chart.